

Fresenius Kabi Oncology Limited
 Regd. Office : B-310, Som Datt Chambers - I, Bhikaji Cama Place, New Delhi - 110066
Unaudited Financial Results for the quarter ended 30th June' 2011

Rs. in Laacs

Particulars	Unaudited for the Quarter ended 30th June' 11	Unaudited for the Quarter ended 30th June' 10	Audited for the Year ended 31st March' 11
Gross Sales (Net of Sales Tax/VAT) / Income from Operations	11545.90	10448.57	41674.89
Less: Excise Duty	302.30	353.17	1336.73
1(a) Net Sales/Income from operation	11243.60	10095.40	40338.16
1(b) Other Operating Income	250.46	246.81	899.28
1 Total Income (1(a)+1(b))	11494.06	10342.21	41237.44
2 Expenditure:			
a. (Increase)/decrease in stock in trade & work in progress	495.05	223.10	704.71
b. Consumption of raw material	3293.45	3124.13	12527.76
c. Purchase of traded goods	55.78	25.16	301.51
d. Employee cost	1407.43	1280.58	5610.50
e. Depreciation	569.60	334.80	1692.00
f. Research & Development	1218.18	1048.19	4547.46
g. Other expenditure	2728.55	1383.90	7947.41
h. Total	9768.04	7419.86	33331.35
3 Profit from operations before other income, interest and exceptional items (1-2)	1726.02	2922.34	7906.09
4 Other Income	41.73	61.91	628.62
5 Profit before interest and exceptional items (3+4)	1767.75	2984.25	8534.71
6 Interest and Finance Charges	538.69	503.16	1802.97
7 Profit after interest but before exceptional items (5-6)	1229.06	2481.09	6731.74
8 Exceptional Items	0.00	0.00	0.00
9 Profit (+)/Loss (-) from ordinary activities before tax (7+8)	1229.06	2481.09	6731.74
10 Provision for taxation:			
-Current tax	245.82	496.22	1399.96
-Deferred tax	(7.56)	166.36	675.68
11 Net Profit(+)/Loss(-) from ordinary activities after tax (9-10)	990.82	1818.51	4656.10
12 Extraordinary item	0.00	0.00	268.07
13 Net Profit(+)/Loss(-) for the period (11+12)	990.82	1818.51	4924.17
14 Paid-up equity share capital (face value of Re 1 Each)	1582.28	1582.28	1582.28
15 Reserves excluding revaluation reserves			52551.82
16 Basic EPS (Excluding Extraordinary item) (in Rs not annualised)	0.63	1.15	2.94
17 Diluted EPS (Excluding Extra-ordinary items) (in Rs not annualised)	0.63	1.15	2.94
18 Basic EPS (Including Extra-ordinary items) (in Rs not annualised)	0.63	1.15	3.11
19 Diluted EPS (Including Extra-ordinary item) (in Rs not annualised)	0.63	1.15	3.11
20 Public Shareholding:			
-Number of shares	15822766	15822766	15822766
-Percentage of Shareholding	10.00	10.00	10.00
21 Promoter & Promoter Group Shareholding			
a) Pledged/Encumbered			
-Number of shares	Nil	Nil	Nil
Percentage of Share (As % of total shareholding of promoter & promoter group)	Nil	Nil	Nil
Percentage of Share (As % of total share capital of the Company)	Nil	Nil	Nil
b) Non Encumbered			
-Number of shares	142404889	142404889	142404889
Percentage of Share (As % of total shareholding of promoter & promoter group)	100.00	100.00	100.00
Percentage of Share (As % of total share capital of the Company)	90.00	90.00	90.00



RB

Unaudited Segmentwise Revenue, Results and Capital Employed for the quarter ended 30th June' 2011

Particulars	Rs in Laacs		
	Unaudited for the Quarter ended 30th June' 11	Unaudited for the Quarter ended 30th June' 10	Audited for the Year ended 31st March' 11
1 Segment Revenue			
A. Formulation	9680.00	8387.14	34549.25
B. Bulk Drug	3431.50	3395.58	19204.85
Total Sales	13111.50	11782.72	53754.09
Less : Inter Segment Revenue	1565.60	1334.15	12079.20
Gross Sales (Net of Sales Tax/VAT) /Income from Operation	11545.90	10448.57	41674.89
2 Segment Results (Profit (+)/Loss (-) before tax, interest and unallocable overheads)			
A. Formulation	2380.67	2622.99	8187.59
B. Bulk Drug	733.29	818.33	4305.44
Total	3113.96	3441.31	12493.03
Less : 1) Interest	538.69	503.16	1802.97
2) Unallocable Expenditure net of unallocable income	1346.21	457.06	3958.32
Total profit before tax	1229.06	2481.09	6731.74
3 Capital Employed (Segment Assets less Segment Liabilities)			
A. Formulation	32999.60	39916.14	41714.40
B. Bulk Drug	16944.62	17331.23	16245.71
C. Unallocable Capital Employed	5167.99	(6218.93)	(3838.73)
Total Capital Employed	55112.21	51028.44	54121.38

Notes on unaudited (Standalone) results for the quarter ended 30th June' 2011

- 1 Net Sales for the current quarter is higher by 11.4% as compared to corresponding previous year quarter.
- 2 Employees related liabilities pertaining to defined benefit plans and deferred taxes have been considered on estimated basis.
- 3 During the quarter, entire long term investment in wholly owned overseas subsidiary Fresenius Kabi Oncology Plc. UK has been disinvested at cost. This has resulted in transfer of Rs. 130 crores of capital employed from formulation segment 3(A) to unallocable segment 3 (C).
- 4 Number of investors' complaints received and disposed of during the quarter ended 30th June' 2011: opening- NIL, received- NIL, disposed of- NIL and pending- NIL.
- 5 The figures of earlier periods have been regrouped and reclassified wherever necessary in line with current period grouping.
- 6 The above results were reviewed by Audit committee and approved by the Board of Directors in the meeting held on 11th August 2011.



By Order of the Board
For Fresenius Kabi Oncology Limited

R.B. Bhargava
Rakesh Bhargava
Chairman

Gurgaon: 11th August' 2011